Clinical Takeaway
Clinical Takeaway Patients presenting with cannabis-induced psychosis have measurable risk for developing schizophrenia spectrum or bipolar disorder, though distinguishing these primary psychiatric conditions from acute cannabis effects remains clinically challenging. Long-term psychiatric monitoring and standardized diagnostic protocols are necessary following cannabis-induced psychotic episodes to identify individuals at risk for persistent mental illness.
#25 Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.
Citation: Javed Mohammad Saad et al.. Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.. BMC psychiatry. 2026. PMID: 41664079.
Design: 6 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: -2
- Preclinical only
Abstract: BACKGROUND: Distinguishing cannabis-induced psychosis from primary psychiatric disorders is difficult and has significant clinical and prognostic implications. Current treatment approaches lack standardized guidelines, potentially leading to the development of schizophrenia spectrum and bipolar disorder. This study systematically reviews the literature and provides a pooled prevalence of later developing these disorders following a cannabis-induced psychosis diagnosis. METHODS: We systematically reviewed Medline, Embase, Web of Science, Google Scholar, and PsychInfo for studies reporting on a group of patients with cannabis-induced psychosis and subsequent diagnoses of schizophrenia spectrum disorder, bipolar disorder, or both. The search was conducted until January 1, 2025. A modified version of the Newcastle-Ottawa scale was used to assess study quality. Random-effects meta-analyses were conducted to calculate pooled mean prevalence. Random-effects meta-regressions were used to identify predictors of higher prevalence. RESULTS: Our strategy identified 13 studies eligible for inclusion with a total population size of 7,515 which reported a total of 16 outcomes of interest. Among cannabis induced psychosis patients, 20% (95% CI:15.8-29.5%) later received a schizophrenia spectrum diagnosis, 5% (95% CI:2.7-6.9%) bipolar and 63% (95% CI:26.8-90.5%) unspecified (both). Compared to individuals receiving a later schizophrenia spectrum disorder diagnosis, patients were 76% less likely to develop bipolar disorder. Later diagnosis of an unspecified disorder showed an approximate 3 folds higher risk with an ARR of 2.52 (95% CI: 1.03-6.15) compared to schizophrenia spectrum disorder alone. CONCLUSIONS: Approximately one in five patients diagnosed with cannabis-induced psychosis will develop schizophrenia spectrum disorder, while one in twenty will be later diagnosed with bipolar disorder.
| |
Have thoughts on this? Share it:
